Caroline Caperton
Allergy & Immunology · Shreveport, LANPI 1861791592
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,655 of the $51,979 with a category attached, or 70.5%. 35 manufacturers reported payments, led by ARS Pharmaceuticals Operations, Inc. at 58.7% of the total. 2025 is the largest year on record at $31,629, 2.6 times the $12,099 reported in 2019. Among allergy & immunology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $135.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ARS Pharmaceuticals Operations, Inc.$31K
- Pfizer$14K
- AstraZeneca$2K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$994
- Aimmune Therapeutics, Inc.$553
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$36,65571%
- Travel & lodging$6,44312%
- Food & beverage$8,69517%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ARS Pharmaceuticals Operations, Inc. | 48 | $30,532 |
| Pfizer | 49 | $14,030 |
| AstraZeneca | 63 | $2,006 |
| GSK | 77 | $1,424 |
| Regeneron Healthcare Solutions, Inc. | 37 | $994 |
| Aimmune Therapeutics, Inc. | 4 | $553 |
| Kaleo, Inc. | 15 | $392 |
| Sanofi | 11 | $282 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $235 |
| Grifols USA, LLC | 6 | $184 |
| Boehringer Ingelheim | 9 | $155 |
| Amgen | 2 | $142 |
| LEO Pharma Inc. | 10 | $141 |
| Ionis Pharmaceuticals, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 2 | $118 |
| Genentech USA, Inc. | 5 | $81 |
| Novartis | 3 | $67 |
| Incyte Corporation | 4 | $61 |
| Greer Laboratories, Inc. | 3 | $57 |
| CSL Behring | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $47 |
| Galderma Laboratories, L.p. | 2 | $40 |
| Biocryst US Sales Co., LLC | 2 | $35 |
| Lilly USA, LLC | 2 | $31 |
| Organon | 3 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Alk-abello, Inc | 1 | $19 |
| Hospira, Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Pharming Healthcare, Inc. | 1 | $17 |
| USWM, LLC | 1 | $17 |
| Merck | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Phadia US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,979 in reported general payments places this provider in the 90th percentile of 62 allergy & immunology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 24 | $92,143 |
| Dupixent SyringeDupilumab | 16 | $83,251 |
| NucalaMepolizumab | 13 | $48,910 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $20,551 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $5,227 |
| Epinephrine | 30 | $4,792 |
| Ipratropium Bromide | 73 | $2,778 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $698 |
| Fluticasone Propionate | 26 | $580 |
| Azelastine Hcl | 19 | $532 |
| Montelukast Sodium | 45 | $441 |
| Famotidine | 18 | $156 |
| Azithromycin | 12 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta | $1,424 | $69,46245 claims |
| Hikma Pharmaceuticals USAEpinephrine | $15 | $4,79230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 allergy & immunology providers in Louisiana.
Other allergy & immunology in Shreveport
- David KaufmanShreveport$678K
- Anand BhatShreveport$9K
- Gonzalo Alvarez del RealShreveport$8K
- Lori JohnsonShreveport$5K
- Hannah FucinariShreveport$4K
- Andria CheramieShreveport$3K
- Priyal UpadhyayShreveport$2K
- Steven WhitedShreveport$451
- Reena MehtaNew Orleans$159K
- Kenneth ParisNew Orleans$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.